Integrin antagonists as potential therapeutic options for the treatment of Crohn’s disease

Volume: 25, Issue: 3, Pages: 263 - 273
Published: Feb 22, 2016
Abstract
Anti-integrin therapy for the treatment of patients with Crohn's disease is rapidly evolving. Two agents, natalizumab and vedolizumab, are approved by the United States Food and Drug Administration for the treatment of Crohn's disease, with vedolizumab the primary anti-integrin used due to a more favorable safety profile. Several other anti-integrins are in various stages of development.This review discusses the current state of anti-integrin...
Paper Details
Title
Integrin antagonists as potential therapeutic options for the treatment of Crohn’s disease
Published Date
Feb 22, 2016
Volume
25
Issue
3
Pages
263 - 273
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.